Abivax S.A.
ABVXNASDAQHealthcare● Active
$103.95
+$2.42(+2.39%)
Market Cap$6.8B
P/E Ratio—
52W High$148.83
52W Low$5.69
Abivax S.A. (ABVX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABVX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 22, 2026EPS Actual
-$0.71
Est. -$0.94 · +23.9%
Revenue
$0.00B
Est. $0.00B · +277.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 22, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
ABVX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 14, 2026 | -$0.88 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 22, 2026 | -$0.94 | -$0.71 | +23.9% | $0.00B | $0.00B | +277.3% |
| ▼ Q1 FY2026 | Mar 23, 2026 | -$1.07 | -$1.22 | -14.2% | $0.00B | $0.00B | -71.4% |
| ▲ Q3 FY2025 | Sep 8, 2025 | -$0.90 | -$0.86 | +4.4% | $0.00B | $0.00B | +70.6% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.68 | -$1.55 | -128.0% | $0.01B | $0.00B | +146.2% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.28 | -$0.70 | +45.5% | $0.00B | $0.00B | +7.0% |
| ▼ Q2 FY2024 | Apr 2, 2024 | -$0.91 | -$1.94 | -112.7% | $0.00B | $0.00B | +3.7% |
| — Q2 FY2023 | Jun 30, 2023 | — | -$1.58 | — | $0.00B | — | — |
Q3 FY2026
Sep 14, 2026
EPS Actual
—
EPS Est.
-$0.88
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 22, 2026Beat
EPS Actual
-$0.71
EPS Est.
-$0.94
EPS Surpr.
+23.9%
Revenue
$0.00B
Q1 FY2026
Mar 23, 2026Miss
EPS Actual
-$1.22
EPS Est.
-$1.07
EPS Surpr.
-14.2%
Revenue
$0.00B
Q3 FY2025
Sep 8, 2025Beat
EPS Actual
-$0.86
EPS Est.
-$0.90
EPS Surpr.
+4.4%
Revenue
$0.00B
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$1.55
EPS Est.
-$0.68
EPS Surpr.
-128.0%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.70
EPS Est.
-$1.28
EPS Surpr.
+45.5%
Revenue
$0.00B
Q2 FY2024
Apr 2, 2024Miss
EPS Actual
-$1.94
EPS Est.
-$0.91
EPS Surpr.
-112.7%
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$1.58
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-1.41 | $-1.41 | $-1.41 | 1 |
| Q3 FY2029 | $-2.40 | $-1.41 | $-0.40 | 1 |
| Q2 FY2029 | $-1.46 | $-1.46 | $-1.46 | 1 |
| Q1 FY2029 | $-2.56 | $-1.50 | $-0.43 | 1 |
| Q4 FY2028 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q3 FY2028 | $-2.54 | $-1.49 | $-0.43 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $-0.0B | $-0.0B | $-0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $-0.0B | $-0.0B | $-0.0B | 2 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $-0.0B | $-0.0B | $-0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 22, 2026 | +23.9% | $124.03 | $121.99 | -1.64% |
| ▼ Q1 FY2026 | Mar 23, 2026 | -14.2% | $120.34 | $115.42 | -4.09% |
| ▲ Q3 FY2025 | Sep 8, 2025 | +4.4% | $88.03 | $90.00 | +2.24% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -128.0% | $7.38 | $7.37 | -0.14% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +45.5% | $10.40 | $10.54 | +1.35% |
| ▼ Q2 FY2024 | Apr 2, 2024 | -112.7% | $13.97 | $14.04 | +0.50% |
| — Q2 FY2023 | Jun 30, 2023 | — | No price data | $8.30 | — |
| ▲ Q4 FY2022 | Dec 31, 2022 | -0.8% | No price data | $8.30 | — |
Q2 FY2026-1.64%
Report Date
May 22, 2026
EPS Beat/Miss
+23.9%
Price Before
$124.03
Price After
$121.99
Q1 FY2026-4.09%
Report Date
Mar 23, 2026
EPS Beat/Miss
-14.2%
Price Before
$120.34
Price After
$115.42
Q3 FY2025+2.24%
Report Date
Sep 8, 2025
EPS Beat/Miss
+4.4%
Price Before
$88.03
Price After
$90.00
Q1 FY2025-0.14%
Report Date
Mar 24, 2025
EPS Beat/Miss
-128.0%
Price Before
$7.38
Price After
$7.37
Q4 FY2024+1.35%
Report Date
Nov 7, 2024
EPS Beat/Miss
+45.5%
Price Before
$10.40
Price After
$10.54
Q2 FY2024+0.50%
Report Date
Apr 2, 2024
EPS Beat/Miss
-112.7%
Price Before
$13.97
Price After
$14.04
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$8.30
Q4 FY2022—
Report Date
Dec 31, 2022
EPS Beat/Miss
-0.8%
Price Before
—
Price After
$8.30
Avg Beat Reaction+0.65%
Avg Miss Reaction-1.24%
Beat Rate4 / 8 quarters
Largest Move-4.09% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABVX ends December
Abivax S.A. (ABVX) most recently reported earnings on May 22, 2026 for Q2 FY2026, posting EPS of $-0.71 — beating the analyst consensus of $-0.94 by +23.9%. The next ABVX earnings date is expected around September 1, 2026.
Each quarter, investors track ABVX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABVX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABVX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABVX earnings · 5 questionsAbivax S.A.'s next earnings report is expected around September 1, 2026. ABVX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABVX historically reports after market close (AMC).
ABVX earnings datewhen is ABVX earningsABVX next earnings datewhen does ABVX report earningsABVX earnings calendar
▸ Source: FMP · Abivax S.A. SEC filings · US GAAP · Abivax S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026